<DOC>
	<DOCNO>NCT00967057</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . It yet know combination chemotherapy regimen effective treat young patient acute lymphoblastic leukemia . PURPOSE : This partially randomized phase III trial study well combination chemotherapy work treat young patient relapse refractory acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Young Patients With Relapsed Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate progression-free survival ( defined time study entry first occurrence progression , relapse , death complete clinical remission , second malignancy ) United Kingdom patient relapse refractory acute lymphoblastic leukemia stratify risk group . - Evaluate whether minimal residual disease ( MRD ) level 10^-4 suitable criterion end induction therapy decide whether chemotherapy stem cell transplantation beneficial patient intermediate-risk disease . Secondary - Use MRD surrogate marker response therapy . OUTLINE : This multicenter study . Patients stratify risk group ( standard v intermediate v high ) participate country ( UK Ireland v Australia New Zealand vs The Netherlands ) . Patients standard-risk disease receive induction therapy , consolidation therapy , intensification therapy , interim maintenance therapy , maintenance therapy . Patients intermediate-risk disease receive induction therapy follow assessment minimal residual disease ( MRD ) . Those whose MRD status &lt; 10^-4 week 5 ( induction therapy ) proceed consolidation therapy follow intensification therapy , interim maintenance therapy , maintenance therapy . Those whose MRD status ≥ 10^-4 week 5 ( induction therapy ) proceed consolidation therapy follow intensification therapy assessment MRD week 13 ( intensification therapy ) . Those whose MRD status ≥ 10^-3 week 13 proceed pre-stem cell transplantation cytoreduction ( FLAD ) follow allogeneic stem cell transplant ( ASCT ) . Those whose MRD status &lt; 10^-3 week 13 proceed directly ASCT . Patients high-risk disease receive induction therapy , consolidation therapy , intensification therapy follow assessment MRD week 13 ( intensification therapy ) . These patient proceed treatment ( FLAD and/or ASCT ) base MRD parameter week 13 patient intermediate-risk disease . - Induction therapy ( week 1-4 ) : Patients randomize 1 2 induction therapy arm . - Arm I : Patients receive idarubicin IV 1 hour day 1 2 ; oral dexamethasone twice daily day 1-5 15-19 ; intrathecal ( IT ) methotrexate day 1 8 ; vincristine sulfate IV day 3 , 10 , 17 , 24 ; pegaspargase intramuscularly ( IM ) day 3 17 asparaginase IM day 3 , 5 , 7 , 9 , 11 , 13 , 15 , 17 , 19 , 21 , 23 , 25 . - Arm II : Patients receive mitoxantrone IV 1 hour day 1 2 . Patients also receive dexamethasone , methotrexate , vincristine sulfate , pegaspargase asparaginase arm I . - Consolidation therapy ( week 5-8 ) : Patients receive oral dexamethasone twice daily day 1-5 ; vincristine sulfate IV day 3 ; IT methotrexate day 8 ; methotrexate IV continuously 36 hour begin day 8 ; pegaspargase IM day 9 asparaginase IM day 9 , 11 , 13 , 15 , 17 , 19 ; leucovorin calcium IV twice day 10 ; cyclophosphamide IV 30 minute etoposide phosphate IV 4 hour day 15-19 . - Intensification therapy ( week 9-13 ) : Patients receive oral dexamethasone twice daily day 1-5 ; vincristine sulfate IV 3 ; IT methotrexate day 1 22 ; cytarabine IV 3 hour twice day 1 , 2 , 8 , 9 ; asparaginase IM day 2 , 4 , 9 , 11 , 23 ; methotrexate IV continuously 36 hour begin day 22 ; leucovorin calcium IV twice day 24 . - Interim maintenance therapy ( week 14-29 ) : Patients receive oral dexamethasone twice daily day 1-5 ; IT methotrexate* day 1 43 ; vincristine sulfate IV day 3 ; high-dose oral methotrexate 4 time day 22 ; oral leucovorin calcium twice day 24 ; oral mercaptopurine daily day 1-42 ; oral methotrexate day 8 , 15 , 29 , 36 ; oral thioguanine day 43-49 ; etoposide phosphate IV 4 hour cyclophosphamide IV 30 minute day 43 50 ; cytarabine IV subcutaneously ( SC ) day 44-47 51-54 . Treatment repeat every 56 day ( 8 week ) 2 course . Patients undergo cranial irradiation start interim maintenance therapy . Patients undergo testicular irradiation concurrently interim maintenance therapy . NOTE : *Patients undergo cranial irradiation receive IT methotrexate . - Maintenance therapy ( week 30-117 ) : Patients receive IT methotrexate* day 15 ; oral dexamethasone twice daily day 1-5 , 29-33 , 57-61 ; vincristine sulfate IV day 1 , 29 , 57 ; oral mercaptopurine daily day 1-84 ; oral methotrexate day 1 , 8 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 . Treatment repeat every 84 day ( 12 week ) 7 course . Patients receive 4 additional week ( course 8 ) maintenance therapy without IT methotrexate . NOTE : *Patients undergo cranial irradiation receive IT methotrexate . - Pre-stem cell transplantation cytoreduction ( FLAD ) : Patients receive fludarabine phosphate IV 30 minute cytarabine 4 hour day 1-5 liposomal daunorubicin citrate IV 2 hour day 1 . Patients also receive filgrastim IV SC begin day 7 continue blood count recover . - ASCT : Patients undergo ASCT ( include condition graft-vs-host disease [ GVHD ] prophylaxis ) accord national transplant guideline base type donor . - Post-transplant immunotherapy : Patients undergo ASCT may receive incremental dos donor lymphocytes infusion response and/or GVHD occur .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute lymphoblastic leukemia ( ALL ) meet 1 follow criterion : In first relapse treatment Has yet receive chemotherapy radiotherapy first relapse Primary refractory disease No mature Bcell ALL Meets criteria one follow risk group : Standardrisk disease : nonTcell Tcell ALL late isolate extramedullary relapse Intermediaterisk disease : nonTcell ALL early isolate extramedullary relapse combine marrow extramedullary relapse ; nonTcell ALL late combine marrow extramedullary relapse isolate marrow relapse ; Tcell ALL early isolate extramedullary relapse Highrisk disease : nonTcell ALL early isolate extramedullary relapse , combine marrow extramedullary relapse , isolated marrow relapse ; nonTcell ALL early isolate marrow relapse ; Tcell ALL early isolate extramedullary relapse , combine marrow extramedullary relapse , isolated marrow relapse ; Tcell ALL early combine marrow extramedullary relapse isolate marrow relapse ; Tcell ALL late combine marrow extramedullary relapse isolate marrow relapse PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior bone marrow transplant</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
</DOC>